IND clearance received from FDA for ISM5939 for solid tumors
“The AI-driven drug discovery industry requires real-world proof-of-concept cases. At Insilico, we have showcased the potential of our proprietary AI platform through consistent milestones in our ongoing pipeline, with 10 AI-enabled drug candidates successfully obtaining IND approvals to date.” says Feng Ren, Ph.D., Co-CEO and Chief Scientific Officer of Insilico Medicine. “We are eager to further validate the company’s in-house R&D pipeline in the clinical stage and to continue advancing AI-powered drug discovery and development for the benefit of patients worldwide.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data